Logo image of PCRX.CA

PHARMACORP RX INC (PCRX.CA) Stock Fundamental Analysis

TSX-V:PCRX - TSX Venture Exchange - CA71714X1050 - Common Stock - Currency: CAD

0.49  -0.02 (-3.92%)

Fundamental Rating

2

Taking everything into account, PCRX scores 2 out of 10 in our fundamental rating. PCRX was compared to 18 industry peers in the Consumer Staples Distribution & Retail industry. While PCRX seems to be doing ok healthwise, there are quite some concerns on its profitability. PCRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PCRX has reported negative net income.
PCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFPCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -100K -200K -300K -400K -500K

1.2 Ratios

PCRX has a worse Return On Assets (-1.47%) than 77.78% of its industry peers.
PCRX's Return On Equity of -1.58% is on the low side compared to the rest of the industry. PCRX is outperformed by 77.78% of its industry peers.
Industry RankSector Rank
ROA -1.47%
ROE -1.58%
ROIC N/A
ROA(3y)-13.92%
ROA(5y)N/A
ROE(3y)-14.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCRX.CA Yearly ROA, ROE, ROICPCRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -5 -10 -15 -20

1.3 Margins

PCRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCRX.CA Yearly Profit, Operating, Gross MarginsPCRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, PCRX has more shares outstanding
PCRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PCRX.CA Yearly Shares OutstandingPCRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 10M 20M 30M 40M
PCRX.CA Yearly Total Debt VS Total AssetsPCRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 500K 1M 1.5M 2M 2.5M

2.2 Solvency

PCRX has an Altman-Z score of 16.06. This indicates that PCRX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 16.06, PCRX belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
PCRX has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
PCRX has a better Debt to Equity ratio (0.03) than 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 16.06
ROIC/WACCN/A
WACCN/A
PCRX.CA Yearly LT Debt VS Equity VS FCFPCRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 1M 2M

2.3 Liquidity

A Current Ratio of 42.61 indicates that PCRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 42.61, PCRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 42.10 indicates that PCRX has no problem at all paying its short term obligations.
PCRX has a better Quick ratio (42.10) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 42.61
Quick Ratio 42.1
PCRX.CA Yearly Current Assets VS Current LiabilitesPCRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M 2.5M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 26.42% over the past year.
EPS 1Y (TTM)26.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCRX.CA Yearly Revenue VS EstimatesPCRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
PCRX.CA Yearly EPS VS EstimatesPCRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCRX.CA Price Earnings VS Forward Price EarningsPCRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCRX.CA Per share dataPCRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2 0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACORP RX INC

TSX-V:PCRX (3/7/2025, 7:00:00 PM)

0.49

-0.02 (-3.92%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.68%
Ins Owner ChangeN/A
Market Cap57.48M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.93
P/tB 2.22
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.25
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.47%
ROE -1.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.92%
ROA(5y)N/A
ROE(3y)-14.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 42.61
Quick Ratio 42.1
Altman-Z 16.06
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-332.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-332.2%
OCF growth 3YN/A
OCF growth 5YN/A